EU AI Act and Agentforce: what life sciences leaders must do before August 2026

The EU AI Act's high-risk obligations enforce on 2 August 2026. Pharma, biotech, and CRO organisations deploying Agentforce in EU operations need a documented use-case inventory, per-use-case risk classification, data governance evidence, human oversight design, technical documentation with logging, and named accountable owners before that date.

• Extraterritorial scope: why UK-headquartered groups with EU operations are in scope
• Risk classification done per Agentforce use case, not per platform
• Layering EU AI Act obligations on top of MHRA, EMA, and GxP
• Six-step readiness model: inventory, classify, govern data, design oversight, document, name owners